Scholtz & Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Scholtz & Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,950	Closed	-$577K	–	51
2022 Q4	$577K	Sell	6,950 -1,245	-15%	-$101K	0.41%	38
2022 Q3	$695K	Buy	+8,195	New	+$691K	0.5%	36

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Scholtz & Company's XBI Position: Q1 2023 in Review

Scholtz & Company sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 6,950 shares — an estimated $577K sold.

Scholtz & Company first reported a position in XBI in Q3 2022 and held it in 2 quarters. The position peaked at $695K in Q3 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Scholtz & Company reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
Scholtz & Company sold 6,950 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $577K.
Scholtz & Company first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 2 quarters.
Scholtz & Company's State Street SPDR S&P Biotech ETF position peaked at $695K in Q3 2022.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Scholtz & Company's 13F filing for Q1 2023, filed 15 May 2023.